RESUMEN
BACKGROUND: Mentoring is vital to career development in academic medicine, and communication underlies all aspects of the mentoring relationship. Although training research mentors has been shown to be effective, few academic medicine faculties have received training in how to mentor. The investigators developed a novel intervention, the Mentor Communication Skills Training for Oncology Faculty ("Comskil Mentor Training") and examined feasibility and preliminary efficacy. METHODS: The study was a single arm pre-post intervention design. The intervention (Comskil Mentor Training) was offered in one virtual 3-hour session and included a didactic lecture with exemplary skill demonstration videos, facilitator-led small group role plays with trained actors, and evaluation. 19 faculty members from 12 departments participated in the training. RESULTS: All participants completed the training. Overall, the training was rated favorably, with more than 80% of participants indicating that they "agreed" or "strongly agreed" with training evaluation. From pre- to post-training, significant improvement was seen in participants' overall self-efficacy to communicate with mentees, as well as participants' overall use of communication skills and mentoring-specific language. CONCLUSIONS: Our findings support the feasibility and preliminary efficacy of a virtually delivered experiential mentor communication skills training program for multidisciplinary clinical and research faculty in oncology.
Asunto(s)
Comunicación , Docentes Médicos , Estudios de Factibilidad , Tutoría , Mentores , Humanos , Masculino , Femenino , Oncología Médica/educación , Evaluación de Programas y Proyectos de Salud , AdultoRESUMEN
Diversifying the future cancer research workforce requires that students engage in cancer research, persist in paths toward science, technology, engineering, mathematics, and medicine (STEMM) fields, and choose cancer research careers. The Summer Clinical Oncology Research Experience (SCORE) Program at Memorial Sloan Kettering, designed in 2010 to engage undergraduate (U) and post-baccalaureate (PB) students from diverse backgrounds in cancer research, is an 8-week summer program pairing an U or PB student with a faculty mentor to conduct cancer research. We report demographics and career paths for 2010-2019 SCORE students. Of 116 students, 112 (97%) attended public universities, and 75 (64%) were in their first 2 years of college. Race/ethnicity was Black/African American, 20 (17%); Hispanic/Latinx, 15 (13%); multiracial, five (4%); Asian, 40 (34%); White/Caucasian, 36 (31%). A total of 112 (97%) identified as female; 47 (41%) were first-generation college students, and 85 (73%) were from immigrant families. As of 2021, 114 (98%) persisted in paths toward STEMM careers: 44 (38%) medical school (MS) students, 14 (12%) residents, two (2%) practicing physicians, 12 (10%) pursuing non-MD STEMM advanced degrees, 21 (18%) working in non-MD STEMM fields, 17 (15%) applying to MS, and 4 (3%) U science majors. Cancer research participation significantly increased from 5% pre- to 84% post-SCORE. A total of 63/116 (54%) students subsequently co-authored 152 peer-reviewed publications, including 105 (69%) in oncology. SCORE engaged underrepresented U and PB students in cancer research, and 98% of these students persisted in paths toward STEMM careers. Long-term follow-up is needed to assess the enduring engagement of these underrepresented students in cancer research.
Asunto(s)
Diversidad, Equidad e Inclusión , Oncología Médica , Grupos Minoritarios , Estudiantes de Medicina , Femenino , Humanos , Selección de Profesión , Oncología Médica/educación , Grupos Minoritarios/educación , Neoplasias , Instituciones AcadémicasRESUMEN
PURPOSE: Although mentorship has been associated with promotion, job satisfaction, and retention, data are limited on the mentorship experience of clinical- versus research-track physicians as well as feasibility and relative priority of formal program components. METHODS AND MATERIALS: Within a single-institution, multi-site, academic network, we implemented a Radiation Oncology AcaDemic Mentorship Program (ROADMAP) for junior faculty. Validated surveys assessing mentee satisfaction were distributed at baseline and 1 year. The statistical analysis included Wilcoxon rank sum and signed tests. Mentees assessed the likelihood to recommend each program component (10-point Likert-type scale), and means with standard error (SE) are reported. RESULTS: Among 42 eligible junior faculty, 36 (86%) opted into the program. The median time since residency was 2.5 years (interquartile range, 1.75-5.25) on the clinical track (nâ¯=â¯12) and 3 years (interquartile range, 2.75-5.00) on the research track (nâ¯=â¯24). At baseline, research-track physicians reported higher satisfaction with mentoring than physicians on the clinical track (2.92 vs 2.16; Pâ¯=â¯.02). Among 32 physicians completing 1 year, overall satisfaction with mentoring increased compared with baseline (2.72 vs 3.87; P < .001), which persisted on subset analysis for both clinical- (2.16 vs 4.03; P < .001) and research-track physicians (2.99 vs 3.77; Pâ¯=â¯.005). At 1 year, 28 mentees (88%) opted to continue the program. Program components were rated 8.25 (SE, 0.37) for mentor-mentee pairings, 7.22 (SE, 0.39) for goal setting, 6.84 (SE, 0.47) for administrative support, 6.69 (SE, 0.44) for peer mentoring, and 6.53 (SE, 0.45) for steering committee oversight. Ratings of peer mentoring were not associated with track (Pâ¯=â¯.59) or years in practice (Pâ¯=â¯.29). CONCLUSIONS: Clinical-track physicians may be less satisfied with mentorship than research-track faculty. However, all junior faculty, regardless of track, appeared to benefit from formalizing dyadic mentor-mentee relationships, goal setting, and peer mentoring. Further work is needed to determine the role of mentorship in addressing physician burnout.
Asunto(s)
Mentores , Oncología por Radiación , Docentes Médicos , Humanos , Evaluación de Programas y Proyectos de Salud , Estudios ProspectivosRESUMEN
Traditional underrepresented minority (URM) groups (African Americans, Hispanic Americans, Native Americans) remain underrepresented among physician-scientists. To address the dearth of URM physician-scientists, in 1993 the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program developed a pipeline program, Gateways to the Laboratory (Gateways), which focuses on increasing the breadth and depth of the URM physician-scientist pipeline by offering an all-encompassing summer research training program which mirrors the life of a physician-scientist. This includes hypothesis-driven research and clinical shadowing opportunities, coupled with weekly career development workshops and extensive multitiered mentoring. Among the 245 alumni who had "graduated" from Gateways as of 2013, 88% have pursued or completed advanced degrees. Among these, 74% completed or are pursuing MD, PhD, or MD-PhD degrees; and 17% completed or are pursuing combined MD-PhD degrees, over one-third of whom are enrolled in the Tri-Institutional MD-PhD Program. Gateways outcomes are compared to other programs with similar missions, which shows that Gateways has been successful at preparing URMs for MD-PhD Programs. The program serves as a model for how to increase the national pool of competitive URM MD-PhD applicants.
Asunto(s)
Diversidad Cultural , Educación de Pregrado en Medicina , Educación Profesional , Grupos Minoritarios , Evaluación de Programas y Proyectos de Salud , Negro o Afroamericano , Hispánicos o Latinos , Humanos , Indígenas Norteamericanos , Selección de PersonalRESUMEN
BACKGROUND: This study was designed to describe patient, disease, and treatment characteristics of women diagnosed with breast cancer at the Breast Examination Center of Harlem (BECH) and to determine whether these characteristics have changed over time. METHODS: Retrospective chart review of women diagnosed with breast cancer at BECH from 2000 to 2008 was performed. Comparisons were made to data from an earlier study period (1995-2000). RESULTS: From 2000 to 2008, 339 women were diagnosed with breast cancer following attendance at BECH-55 % were black, 39 % Hispanic, 5 % of other race/ethnicity; 52 % had no health insurance. Hispanic patients were significantly more likely to have no health insurance compared with black patients (p = 0.0091); 29 % of patients had preinvasive disease and 36.5 % had stage I disease. Almost 40 % of the entire group was followed for <1 year. Five-year overall survival for the entire group was 83 % (95 % CI, 75-89 %) and 79 % for 188 Black women (95 % CI, 68-87 %). Compared with the earlier study period (1995-2000), fewer patients presented with palpable masses (45.4 vs. 67 %), and more had either stage 0 or stage I disease (65.6 vs. 46 %). CONCLUSIONS: Women diagnosed with breast cancer at BECH are predominantly Black and Hispanic, and most of these patients do not have health insurance. An increasing proportion of women diagnosed with breast cancer are presenting with nonpalpable, early-stage disease. Despite improved access to breast cancer screening, early stage at diagnosis, and access to appropriate management, these ethnic minorities continue to have poor outcomes and are poorly compliant with follow-up.
Asunto(s)
Neoplasias de la Mama/diagnóstico , Carcinoma Ductal de Mama/diagnóstico , Carcinoma Intraductal no Infiltrante/diagnóstico , Carcinoma Lobular/diagnóstico , Detección Precoz del Cáncer/estadística & datos numéricos , Mamografía/estadística & datos numéricos , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/epidemiología , Carcinoma Ductal de Mama/epidemiología , Carcinoma Ductal de Mama/mortalidad , Carcinoma Intraductal no Infiltrante/epidemiología , Carcinoma Intraductal no Infiltrante/mortalidad , Carcinoma Lobular/epidemiología , Carcinoma Lobular/mortalidad , Etnicidad , Femenino , Estudios de Seguimiento , Accesibilidad a los Servicios de Salud , Humanos , Cobertura del Seguro , Persona de Mediana Edad , Estadificación de Neoplasias , New York/epidemiología , Pronóstico , Índice de Severidad de la Enfermedad , Tasa de Supervivencia , Adulto JovenRESUMEN
OBJECTIVE: To determine the frequency of cancelled stereotactic biopsy due to non-visualisation of calcifications, and assess associated features and outcome data. METHODS: A retrospective review was performed on 1,874 patients scheduled for stereotactic-guided breast biopsy from 2009 to 2011. Medical records and imaging studies were reviewed. RESULTS: Of 1,874 stereotactic biopsies, 76 (4 %) were cancelled because of non-visualisation of calcifications. Prompt histological confirmation was obtained in 42/76 (55 %). In 28/76 (37 %) follow-up mammography was performed, and 7/28 subsequently underwent biopsy. Of 27 without biopsy, 21 (78 %) had follow-up. Nine cancers (9/49, 18 %) were found: 6 ductal carcinoma in situ (DCIS), 3 infiltrating ductal carcinoma (IDC). Of 54 patients with either biopsy or at least 2 years' follow-up, 9 (17 %) had cancer (95 % CI 8-29). Cancer was present in 7/42 (17 %, 95 % CI 7-31 %) lesions that had prompt histological confirmation (DCIS = 5, IDC = 2) and in 2/28 (7 %, 95 % CI 0.8-24 %) lesions referred for follow-up (DCIS = 1, IDC = 1). Neither calcification morphology (P = 0.2), patient age (P = 0.7), breast density (P = 1.0), personal history (P = 1.0) nor family history of breast cancer (P = 0.5) had a significant association with cancer. CONCLUSION: Calcifications not visualised on the stereotactic unit are not definitely benign and require surgical biopsy or follow-up. No patient or morphological features were predictive of cancer. KEY POINTS: ⢠Half of cancelled stereotactic biopsies were due to non-visualisation of calcified foci. ⢠This reflects the improved detection of calcifications by digital mammography. ⢠Calcifications too faint for the stereotactic technique require alternative biopsy or follow-up ⢠17 % of patients with biopsy or at least 2 years' follow-up had cancer. ⢠No patient/morphological features were found to aid selection for re-biopsy vs. follow-up.
Asunto(s)
Neoplasias de la Mama/diagnóstico por imagen , Calcinosis/diagnóstico por imagen , Carcinoma Ductal de Mama/diagnóstico por imagen , Carcinoma Intraductal no Infiltrante/diagnóstico por imagen , Mamografía/estadística & datos numéricos , Adulto , Anciano , Anciano de 80 o más Años , Biopsia/métodos , Mama/patología , Neoplasias de la Mama/patología , Carcinoma Ductal de Mama/patología , Carcinoma Intraductal no Infiltrante/patología , Femenino , Humanos , Persona de Mediana Edad , Estudios Retrospectivos , Técnicas EstereotáxicasRESUMEN
Focal extravasated mucin (EM) with benign or atypical epithelium is a rare finding at breast core needle biopsy (CNB) and usually prompts surgical excision to rule out mucin-producing carcinoma. In the largest detailed series to date, we assessed surgical outcomes in lesions yielding EM with atypical or nonatypical epithelium at CNB. With IRB approval, we retrospectively reviewed 28 consecutive atypical and nonatypical CNBs with EM that underwent surgical excision at our center over a 22-year period. CNB imaging and pathologic findings were concordant if pathology sufficiently explained the radiologic features of the lesions. Pathologic findings in CNB and excision specimens were correlated. Statistical analysis was performed. CNBs sampled mammographic calcifications in 25/28 (89%) women and a mass in 3/28 (11%). All cases had concordant pathologic and imaging findings. At CNB, the epithelium associated with EM was atypical in 18/28 (64%) lesions and nonatypical in 10 (36%). Cancer (one mucinous carcinoma; three ductal carcinoma in situ) was present in 4/28 excision specimens (14%; 95% confidence intervals [CI], 4%-33%). All carcinomas were in lesions with epithelial atypia at CNB (4/18; 22%; 95% CI, 6%-48%) versus none (0/10; 0%; 95% CI, 0%-31%) in nonatypical lesions at CNB; this difference was not statistically significant (p = 0.3). Surgery is warranted for lesions yielding EM with atypia at CNB due to the high (22%) prevalence of cancer. Our data suggest that surgical excision of lesions yielding EM without epithelial atypia at CNB may not be necessary provided that imaging and pathologic findings are concordant.
Asunto(s)
Biopsia con Aguja Gruesa/métodos , Mama/patología , Mucinas , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Estudios Retrospectivos , Ultrasonografía IntervencionalRESUMEN
BACKGROUND: No consensus exists on the need to excise breast lesions that yield classic lobular carcinoma in situ (LCIS) or atypical lobular hyperplasia (ALH) (known together as classic lobular neoplasia [LN]) as the highest risk lesion at percutaneous core-needle biopsy (CNB). Here, the authors report findings from 72 consecutive lesions with LN at CNB and prospective surgical excision (EXB). METHODS: Lesions that yielded LN at CNB at the authors' center have been referred for EXB since June 2004, regardless of imaging-histologic concordance. A lesion was "concordant" if histologic findings provided sufficient explanation for imaging. An upgrade consisted of ductal carcinoma in situ and/or invasive carcinoma at EXB. Statistical analysis, including 95% confidence intervals (CIs), was performed. RESULTS: Between June 2004 and May 2009, CNB of 85 consecutive lesions yielded LN without other high-risk histologies. Eighty of 85 lesions (94%) underwent prospective EXB. Seventy-two of 85 lesions (90%; 42 LCIS, 30 ALH) had concordant imaging-histologic findings. EXB yielded low-grade carcinoma in 2 of 72 cases (3%; 95% CI, 0%-9%). In both patients, stereotactic, 11-gauge, vacuum-assisted biopsy of calcifications yielded calcifications in benign parenchyma and ALH. CNB results were discordant in 8 of 80 lesions (10%; 4 LCIS, 4 ALH), and EXB yielded cancer in 3 of those 8 lesions (38%; 95% CI, 9%-76%). The upgrade rate was significantly higher for discordant lesions versus concordant lesions (38% vs 3%; P < .01). CONCLUSIONS: Prospective excision of LN identified carcinoma in 3% (95% CI, 0%-9%) of concordant cases versus 38% (95% CI, 9%-76%) of discordant cases. The current data provide an unbiased assessment of the upgrade rate of LN diagnosed at CNB.
Asunto(s)
Neoplasias de la Mama/patología , Carcinoma in Situ/patología , Carcinoma Lobular/patología , Hiperplasia/patología , Adulto , Anciano , Biopsia con Aguja Gruesa , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/cirugía , Carcinoma in Situ/diagnóstico por imagen , Carcinoma in Situ/cirugía , Carcinoma Lobular/diagnóstico por imagen , Carcinoma Lobular/cirugía , Femenino , Humanos , Persona de Mediana Edad , Lesiones Precancerosas/diagnóstico por imagen , Lesiones Precancerosas/patología , Lesiones Precancerosas/cirugía , RadiografíaRESUMEN
The objective of this study was to evaluate the impact of tamoxifen treatment on amount of fibroglandular tissue (FGT), background parenchymal enhancement (BPE), and cysts on breast MRI. Retrospective search identified 96 women with breast cancer who had a breast MRI both before and during adjuvant tamoxifen therapy between 2002 and 2008. After exclusion of all irradiated breasts, 88 women were eligible. Two readers blinded to tamoxifen treatment status independently rated level of BPE, amount of FGT, and cysts using a 4-point categorical scale: BPE--Minimal, Mild, Moderate, Marked; FGT--Fatty, Scattered, Heterogeneously Dense (HD), Dense; Cysts--Minimal, Mild, Moderate, Marked. A consensus interpretation was reached in cases of disagreement. During tamoxifen, there was a significant shift from higher to lower degree BPE, cysts, and FGT compared with before tamoxifen. BPE, cysts and FGT decreased in 68% (60/88), 38% (33/88), and 40% (35/88) of women during tamoxifen (p<0.001 for all measures). After the exclusion of all cases with minimal BPE, cysts, or FGT on the pre-tamoxifen MRI, the percentage of women demonstrating a decrease in these factors increased to 81% (60/74), 77% (33/43), and 41% (35/86), respectively. Exclusion of patients treated with chemotherapy did not substantially change these results. The percentage of women with decreases in FGT and cysts increased with greater duration on tamoxifen, whereas decreases in BPE were detected early in treatment (<90 days) and did not change substantially with longer duration on tamoxifen. A significant association exists between treatment with tamoxifen and decreases in BPE, cysts, and FGT on breast MRI.
Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Quiste Mamario/diagnóstico , Quiste Mamario/patología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Imagen por Resonancia Magnética/métodos , Tamoxifeno/uso terapéutico , Adulto , Anciano , Quiste Mamario/tratamiento farmacológico , Quimioterapia Adyuvante , Femenino , Humanos , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento , Adulto JovenRESUMEN
OBJECTIVE: The objective of our study was to determine the frequency of cancer at surgery in breast lesions yielding papilloma at MRI-guided 9-gauge vacuum-assisted biopsy (VAB) and to determine whether any features are associated with cancer upgrade. MATERIALS AND METHODS: For this study, 1487 MRI-guided vacuum-assisted biopsies performed from January 2004 to March 2011 were reviewed. Lesions yielding papilloma were identified and classified as papilloma with or without atypia. Surgical findings were reviewed to determine the cancer rate. Statistical analysis was performed and 95% CIs were calculated. RESULTS: Papilloma was identified in 75 of the 1487 MRI-guided vacuum-assisted biopsies (5%). These 75 papillomas occurred in 73 women with a median age of 49 years (age range, 27-70 years). Of the 75 papillomas, 25 (33%) had atypia and 50 (67%) did not on core needle biopsy. Subsequent surgery of 67 of the 75 papillomas (89%) yielded ductal carcinoma in situ (DCIS) in four (6%; 95% CI, 2-15%). Surgery yielded DCIS in two of 23 papillomas with atypia (9%; 95% CI, 1-28%) at MRI-guided VAB and in two of 44 papillomas without atypia (5%; 95% CI, 0.4-16%) at MRI-guided VAB; these cancer rates did not differ significantly (p=0.6). Postmenopausal status (p=0.04) and histologic size of less than 0.2 cm (p=0.04) had a significant association with the cancer upgrade rate. CONCLUSION: Papilloma with or without atypia was found in 5% of patients who underwent MRI-guided VAB during the study period. Surgery revealed cancer in 6%. DCIS was found at surgery in 9% of lesions yielding papilloma with atypia versus 5% of lesions yielding papilloma without atypia. For lesions yielding papilloma with or without atypia at MRI-guided VAB, surgical excision is warranted.
Asunto(s)
Biopsia con Aguja Gruesa , Neoplasias de la Mama/diagnóstico , Imagen por Resonancia Magnética Intervencional , Papiloma/diagnóstico , Adulto , Anciano , Biopsia con Aguja Gruesa/métodos , Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Carcinoma Intraductal no Infiltrante/diagnóstico , Carcinoma Intraductal no Infiltrante/patología , Carcinoma Intraductal no Infiltrante/cirugía , Femenino , Humanos , Persona de Mediana Edad , Papiloma/patología , Papiloma/cirugía , VacioRESUMEN
PURPOSE: To determine the rate of canceled magnetic resonance (MR) imaging-guided breast biopsies due to nonvisualization of the lesion and to assess associated features and outcome data for these cases. MATERIALS AND METHODS: With the approval of the institutional review board, a HIPAA-compliant retrospective review, in which the requirement for informed consent was waived, was performed for 907 patients scheduled for MR imaging-guided breast biopsy from 2004 to 2008. In 70 patients, MR imaging biopsy was canceled due to lesion nonvisualization. Medical records and imaging studies were reviewed to identify patient, parenchymal, lesion features and outcome data. Statistical analysis was performed with the Fisher exact test. The 95% confidence interval (CI) was calculated. RESULTS: Cancellation of MR-guided biopsy due to lesion nonvisualization occurred in 8% (70 of 907) of patients and in 8% (74 of 911) of lesions. Factors associated with a significantly higher cancellation rate included marked and moderate versus mild and minimal background parenchymal enhancement (38 of 316 [12%] vs 32 of 591 [5%], P = .001), extremely and heterogeneously dense versus scattered fibroglandular densities and fatty parenchymal volume (64 of 712 [9%] vs six of 195 [3%], P = .006), and lesions 1 cm or less in size (52 of 520 [10%] vs 22 of 391 [6%], P = .02).The rate of cancellation per year was highest in the first year, with a decrease in subsequent years (14 of 102 [14%] vs 56 of 805 [7%], P = .025). A significantly lower rate was found in women with synchronous breast cancer (nine of 240 [4%] vs 61 of 667 [9%], P = .007), and a significantly higher rate was found in women with a history of cancer (35 of 315 [11%] vs 35 of 592 [6%], P = .01). Among 58 women who had MR imaging follow-up, no cancers were identified. Among three women who underwent mastectomy after cancellation, one had ductal carcinoma in situ in the same quadrant as the MR-depicted lesion. The cancer detection rate among 61 women who underwent either MR imaging or pathologic follow-up was 2% (one of 61) (95% CI: 0.4%, 9%). CONCLUSION: MR imaging-guided breast biopsy was canceled due to lesion nonvisualization in 8% of the patients. Although the cancer detection rate among the lesions for which biopsy was canceled is low (95% CI: 0%, 9%), short-term follow-up MR imaging is prudent.
Asunto(s)
Neoplasias de la Mama/diagnóstico , Imagen por Resonancia Magnética , Adulto , Anciano , Biopsia con Aguja/métodos , Biopsia con Aguja/estadística & datos numéricos , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
PURPOSE: To compare total choline concentrations ([Cho]) and water-to-fat (W/F) ratios of subtypes of malignant lesions, benign lesions, and normal breast parenchyma and determine their usefulness in breast cancer diagnosis. Reference standard was histology. MATERIALS AND METHODS: In this HIPPA compliant study, proton MRS was performed on 93 patients with suspicious lesions (>1 cm) who underwent MRI-guided interventional procedures, and on 27 prospectively accrued women enrolled for screening MRI. (W/F) and [Cho] values were calculated using MRS data. RESULTS: Among 88 MRS-evaluable histologically-confirmed lesions, 40 invasive ductal carcinoma (IDC); 10 invasive lobular carcinoma (ILC); 4 ductal carcinoma in situ (DCIS); 3 invasive mammary carcinoma (IMC); 31 benign. No significant difference observed in (W/F) between benign lesions and normal breast tissue. The area under curve (AUC) of receiver operating characteristic (ROC) curves for discriminating the malignant group from the benign group were 0.97, 0.72, and 0.99 using [Cho], (W/F) and their combination as biomarkers, respectively. (W/F) performs significantly (P < 0.0001;AUC = 0.96) better than [Cho] (AUC = 0.52) in differentiating IDC and ILC lesions. CONCLUSION: Although [Cho] and (W/F) are good biomarkers for differentiating malignancy, [Cho] is a better marker. Combining both can further improve diagnostic accuracy. IDC and ILC lesions have similar [Cho] levels but are discriminated using (W/F) values.
Asunto(s)
Tejido Adiposo/metabolismo , Agua Corporal/metabolismo , Enfermedades de la Mama/diagnóstico , Neoplasias de la Mama/diagnóstico , Mama/fisiología , Colina/metabolismo , Espectroscopía de Resonancia Magnética/métodos , Adulto , Anciano , Área Bajo la Curva , Biomarcadores/metabolismo , Enfermedades de la Mama/patología , Neoplasias de la Mama/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Modelos Estadísticos , Curva ROCRESUMEN
OBJECTIVE: Background parenchymal enhancement on breast MRI refers to normal enhancement of the patient's fibroglandular tissue. The aim of this study was to determine the effect of background parenchymal enhancement on short-interval follow-up, biopsy, and cancer detection rate on baseline screening MRI in a high-risk group. MATERIALS AND METHODS: Two hundred fifty baseline high-risk screening MRI examinations were reviewed. For each, the background parenchymal enhancement pattern was recorded (minimal, ≤ 25%; mild, 26-50%; moderate, 51-75%; and marked, > 75%), as were BI-RADS category, biopsy rate, and final pathology result. Results were compared for each enhancement category. RESULTS: Of the 250 MRI examinations, 24.8% showed minimal enhancement; 34%, mild; 24%, moderate; and 17.2%, marked enhancement. Women with minimal enhancement had a significantly higher number of BI-RADS categories 1 and 2 examinations (64.5%) than women with mild (38.8%), moderate (40%), or marked (25.6%) enhancement. The BI-RADS category 3 rate was 43.6% overall and was significantly lower for women with minimal enhancement (27.4% vs 47.1% for women with mild, 45.0% for women with moderate, and 58.1% for women with marked enhancement). At follow-up, 86.2% of the BI-RADS 3 lesions were converted to BI-RADS category 1 or 2 and 13.8% were converted to BI-RADS 4, with a malignancy rate of 0.9% for lesions undergoing short-interval follow-up. There was no significant difference in biopsy rate or cancer detection rate among enhancement categories. CONCLUSION: Mild, moderate, and marked background parenchymal enhancement is associated with a significantly lower rate of BI-RADS categories 1 and 2 assessments and a significantly higher rate of BI-RADS category 3 assessments than minimal enhancement. There was no significant difference in biopsy rate or cancer detection rate among the enhancement categories.
Asunto(s)
Neoplasias de la Mama/diagnóstico , Aumento de la Imagen/métodos , Imagen por Resonancia Magnética/métodos , Adolescente , Adulto , Anciano , Biopsia , Neoplasias de la Mama/patología , Medios de Contraste , Femenino , Humanos , Interpretación de Imagen Asistida por Computador , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Estudios RetrospectivosRESUMEN
Screening mammography can detect breast cancer before it becomes clinically apparent. However, the screening process identifies many false-positive findings for each cancer eventually confirmed. Additional tools are available to help differentiate spurious findings from real ones and to help determine when tissue sampling is required, when short-term follow-up will suffice, or whether the finding can be dismissed as benign. These tools include additional diagnostic mammographic views, breast ultrasound, breast MRI, and, when histologic evaluation is required, percutaneous biopsy. The imaging evaluation of a finding detected at screening mammography proceeds most efficiently, cost-effectively, and with minimization of radiation dose when approached in an evidence-based manner. The appropriateness of the above-referenced tools is presented here as they apply to a variety of findings often encountered on screening mammography; an algorithmic approach to workup of these potential scenarios is also included. The recommendations put forth represent a compilation of evidence-based data and expert opinion of the ACR Appropriateness Criteria(®) Expert Panel on Breast Imaging.
Asunto(s)
Neoplasias de la Mama/diagnóstico , Diagnóstico por Imagen/normas , Adhesión a Directriz/normas , Tamizaje Masivo/normas , Guías de Práctica Clínica como Asunto , Biopsia/normas , Neoplasias de la Mama/patología , Calcinosis/diagnóstico , Diagnóstico Diferencial , Medicina Basada en la Evidencia , Femenino , Humanos , Imagen por Resonancia Magnética/normas , Mamografía/normas , Palpación , Pautas de la Práctica en Medicina , Dosis de Radiación , Sociedades Médicas , Ultrasonografía Mamaria/normas , Estados UnidosRESUMEN
OBJECTIVE: The purpose of this article is to determine the cancer detection and biopsy rate among women who have breast MRI screening solely on the basis of a personal history of breast cancer. MATERIALS AND METHODS: This retrospective review of 1,699 breast MRI examinations performed from 1999 to 2001 yielded 144 women with prior breast cancer but no family history who commenced breast MRI screening during that time. Minimal breast cancer was defined as ductal carcinoma in situ (DCIS) or node-negative invasive breast cancer < 1 cm in size. RESULTS: Of 144 women, 44 (31% [95% CI, 15-29%]) underwent biopsies prompted by MRI examination. Biopsies revealed malignancies in 17 women (12% [95% CI, 7-18%]) and benign findings only in 27 women (19% [95% CI, 13-26%]). Of the 17 women in whom cancer was detected, seven also had benign biopsy results. In total, 18 malignancies were found. One woman had two metachronous cancers. MRI screening resulted in a total of 61 biopsies, with a positive predictive value (PPV) of 39% (95% CI, 27-53%). The malignancies found included 17 carcinomas and one myxoid liposarcoma. Of the 17 cancers, 12 (71%) were invasive, five (29%) were DCIS, and 10 (59%) were minimal breast cancers. Of 17 cancers, 10 were detected by MRI only. The 10 cancers detected by MRI only, versus seven cancers later found by other means, were more likely to be DCIS (4/10 [40%] vs 1/7 [14%]; p = 0.25) or minimal breast cancers (7/10 [70%] vs 3/7 [43%]; p = 0.26). CONCLUSION: We found that breast MRI screening of women with only a personal history of breast cancer was clinically valuable finding malignancies in 12%, with a reasonable biopsy rate (PPV, 39%).
Asunto(s)
Neoplasias de la Mama/diagnóstico , Imagen por Resonancia Magnética/métodos , Tamizaje Masivo/métodos , Adulto , Anciano , Femenino , Humanos , Persona de Mediana Edad , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Adulto JovenRESUMEN
OBJECTIVE: The objective of our study was to assess the experiences and preferences of radiology residents with respect to breast imaging. MATERIALS AND METHODS: We surveyed radiology residents at 26 programs in New York and New Jersey. Survey topics included plans for subspecialty training, beliefs, and attitudes toward breast imaging and breast cancer screening and the likelihood of interpreting mammography in the future. RESULTS: Three hundred forty-four residents completed the survey (response rate, 62%). The length of time spent training in breast imaging varied from no dedicated time (37%) to 1-8 weeks (40%) to more than 9 weeks (23%). Most respondents (97%) agreed that mammography is important to women's health. More than 85% of residents believed that mammography should be interpreted by breast imaging specialists. Respondents shared negative views about mammography, agreeing with statements that the field was associated with a high risk of malpractice (99%), stress (94%), and low reimbursement (68%). Respondents endorsed several positive attributes of mammography, including job availability (97%), flexible work schedules (94%), and few calls or emergencies (93%). Most radiology residents (93%) said that they were likely to pursue subspecialty training, and 7% expressed interest in breast imaging fellowships. CONCLUSION: Radiology residents' negative and positive views about mammography seem to be independent of time spent training in mammography and of future plans to pursue fellowship training in breast imaging. Systematic assessment of the plans and preferences of radiology residents can facilitate the development of strategies to attract trainees to careers in breast imaging.
Asunto(s)
Enfermedades de la Mama/diagnóstico por imagen , Conocimientos, Actitudes y Práctica en Salud , Internado y Residencia , Mamografía , Pautas de la Práctica en Medicina/estadística & datos numéricos , Adulto , Distribución de Chi-Cuadrado , Femenino , Predicción , Humanos , Masculino , Encuestas y CuestionariosRESUMEN
BACKGROUND: Screening mammography rates vary geographically and have recently declined. Inadequate mammography resources in some areas may impair access to this technology. We assessed the relationship between availability of mammography machines and the use of screening. METHODS: The location and number of all mammography machines in the United States were identified from US Food and Drug Administration records of certified facilities. Inadequate capacity was defined as <1.2 mammography machines per 10,000 women age 40 or older, the threshold required to meet the Healthy People 2010 target screening rate. The impact of capacity on utilization was evaluated in 2 cohorts: female respondents age 40 or older to the 2006 Behavioral Risk Factor Surveillance System survey (BRFSS) and a 5% nationwide sample of female Medicare beneficiaries age 65 or older in 2004-2005. RESULTS: About 9% of women in the BRFSS cohort and 13% of women in the Medicare cohort lived in counties with <1.2 mammography machines per 10,000 women age 40 or older. In both cohorts, residence in a county with inadequate mammography capacity was associated with lower odds of a recent mammogram (adjusted odds ratio in BRFSS: 0.89, 95% CI: 0.80-0.98, P < 0.05; adjusted odds ratio in Medicare: 0.86, 95% CI: 0.85-0.87, P < 0.05), controlling for demographic and health care characteristics. CONCLUSION: In counties with few or no mammography machines, limited availability of imaging resources may be a barrier to screening. Efforts to increase the number of machines in low-capacity areas may improve mammography rates and reduce geographic disparities in breast cancer screening.
Asunto(s)
Equipo para Diagnóstico/provisión & distribución , Geografía , Accesibilidad a los Servicios de Salud , Tamizaje Masivo/instrumentación , Ultrasonografía Mamaria/estadística & datos numéricos , Adulto , Anciano , Anciano de 80 o más Años , Sistema de Vigilancia de Factor de Riesgo Conductual , Estudios de Cohortes , Femenino , Humanos , Medicare , Persona de Mediana Edad , Ultrasonografía Mamaria/instrumentación , Estados UnidosRESUMEN
Breast tumor volume measured on MRI has been used to assess response to neoadjuvant chemotherapy. However, accurate and reproducible delineation of breast lesions can be challenging, since the lesions may have complicated topological structures and heterogeneous intensity distributions. In this article, the authors present an advanced computerized method to semiautomatically segment tumor volumes on T1-weighted, contrast-enhanced breast MRI. The method starts with manual selection of a region of interest (ROI) that contains the lesion to be segmented in a single image, followed by automated separation of the lesion volume from its surrounding breast parenchyma by using a unique combination of the image processing techniques including Gaussian mixture modeling and a marker-controlled watershed transform. Explicitly, the Gaussian mixture modeling is applied to an intensity histogram of the pixels inside the ROI to distinguish the tumor class from other tissues. Based on the ROI and the intensity distribution of the tumor, internal and external markers are determined and the tumor contour is delineated using the marker-controlled watershed transform. To obtain the tumor volume, the segmented tumor in one slice is propagated to the adjacent slice to form an ROI in that slice. The marker-controlled watershed segmentation is then used again to obtain a tumor contour in the propagated slice. This procedure is terminated when there is no lesion in an adjacent slice. To reduce measurement variations possibly caused by the manual selection of the ROI, the segmentation result is refined based on an automatically determined ROI based on the segmented volume. The algorithm was applied to 13 patients with breast cancer, prospectively accrued prior to beginning neoadjuvant chemotherapy. Each patient had two MRI scans, a baseline MRI examination prior to commencing neoadjuvant chemotherapy and a 1 week follow-up after receiving the first dose of neoadjuvant chemotherapy. Blinded to the computer segmentation results, two experienced radiologists manually delineated all tumors independently. The computer results were then compared with the manually generated results using the volume overlap ratio, defined as the intersection of the computer- and radiologist-generated tumor volumes divided by the union of the two. The algorithm reached overall overlap ratios of 62.6% +/- 9.1% and 61.0% +/- 11.3% in comparison to the two manual segmentation results, respectively. The overall overlap ratio between the two radiologists' manual segmentations was 64.3% +/- 10.4%. Preliminary results suggest that the proposed algorithm is a promising method for assisting in tumor volume measurement in contrast-enhanced breast MRI.
Asunto(s)
Adenocarcinoma/diagnóstico , Inteligencia Artificial , Neoplasias de la Mama/diagnóstico , Gadolinio DTPA , Aumento de la Imagen/métodos , Interpretación de Imagen Asistida por Computador/métodos , Imagen por Resonancia Magnética/métodos , Reconocimiento de Normas Patrones Automatizadas/métodos , Adulto , Algoritmos , Medios de Contraste , Femenino , Humanos , Persona de Mediana Edad , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
OBJECTIVE: The purpose of this study was to determine the characteristics of fellowship programs offering breast imaging training and their success in filling positions. CONCLUSION: A comprehensive list of fellowship training opportunities in breast imaging may help potential applicants identify relevant programs.
Asunto(s)
Neoplasias de la Mama/diagnóstico por imagen , Becas/estadística & datos numéricos , Radiología/educación , Humanos , Mamografía , Sociedades Médicas , Estados UnidosRESUMEN
OBJECTIVE: The purpose of our study was to determine the frequency of complete removal of the imaging target at MRI-guided vacuum-assisted biopsy of breast cancer and to assess the residual cancer rate at surgery in these lesions. MATERIALS AND METHODS: With the approval of our institutional review board, retrospective review was performed of 416 consecutive lesions that underwent MRI-guided 9-gauge vacuum-assisted biopsy, of which 76 (18%) yielded cancer. Medical and pathology records were reviewed. RESULTS: Vacuum-assisted biopsy histology in 76 cancers was ductal carcinoma in situ in 39 (51%) and invasive cancer in 37 (49%). Median MRI lesion size in these 76 cancers was 1.2 cm (range, 0.4-8.0 cm). The median number of samples obtained was 12 (range, 6-24 samples). Among 76 cancers, the MRI target was completely excised in 23 (30% [95% CI, 20-42%]), sampled in 52 (69% [57-79%]), and possibly missed in one (1% [0-7%]). Complete MRI target excision rather than sampling was significantly more likely in lesions < or = 1 cm than in lesions >1 cm (18/34 = 53% vs 5/41 = 12%; p < 0.001). Surgery, performed in 67 of 76 cancers, showed residual cancer in 55 (82% [71-90%]). The residual cancer rate was significantly lower if the MRI target was completely excised rather than sampled (14/22 = 64% vs 40/44 = 91%; p < 0.02). CONCLUSION: Complete excision of the MRI target occurred in 30% of breast cancers diagnosed at MRI-guided vacuum-assisted biopsy. Among cancers in which the MRI target was percutaneously excised, surgery yielded residual cancer in 64%. Complete removal of the MRI target does not ensure complete histologic excision of the cancer.